Drug intelligence / Profile preview

JMKX003676

Development stage: Preclinical
Lead developer: Zhejiang Hangyu Pharmaceutical
Modality: Small Molecules
Administration: Oral

Overview

JMKX003676 is an investigational small molecule antifungal agent being developed by Jemincare. It is targeted toward the treatment of fungal infections. As of current public pipeline disclosures, specific details regarding its molecular target, mechanism of action, and clinical development phase have not been released. The drug is part of Jemincare's internal research and development portfolio focusing on infectious diseases, utilizing a small molecule modality to address fungal pathogens.

Beyond the preview

Go deeper on JMKX003676.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on JMKX003676.

Explore the full profile